BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 30417100)

  • 1. TET2 coactivates gene expression through demethylation of enhancers.
    Wang L; Ozark PA; Smith ER; Zhao Z; Marshall SA; Rendleman EJ; Piunti A; Ryan C; Whelan AL; Helmin KA; Morgan MA; Zou L; Singer BD; Shilatifard A
    Sci Adv; 2018 Nov; 4(11):eaau6986. PubMed ID: 30417100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour suppressor TET2 safeguards enhancers from aberrant DNA methylation and epigenetic reprogramming in ERα-positive breast cancer cells.
    Lyu R; Zhu X; Shen Y; Xiong L; Liu L; Liu H; Wu F; Argueta C; Tan L
    Epigenetics; 2022 Oct; 17(10):1180-1194. PubMed ID: 34689714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TET2 directs mammary luminal cell differentiation and endocrine response.
    Kim MR; Wu MJ; Zhang Y; Yang JY; Chang CJ
    Nat Commun; 2020 Sep; 11(1):4642. PubMed ID: 32934200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TET2 is a component of the estrogen receptor complex and controls 5mC to 5hmC conversion at estrogen receptor cis-regulatory regions.
    Broome R; Chernukhin I; Jamieson S; Kishore K; Papachristou EK; Mao SQ; Tejedo CG; Mahtey A; Theodorou V; Groen AJ; D'Santos C; Balasubramanian S; Farcas AM; Siersbæk R; Carroll JS
    Cell Rep; 2021 Feb; 34(8):108776. PubMed ID: 33626359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of TET2 gene expression and 5mC oxidation in breast cancer cells by estrogen signaling.
    Zhu X; Xiong L; Lyu R; Shen Y; Liu L; Li S; Argueta C; Tan L
    Biochem Biophys Res Commun; 2022 Jan; 589():240-246. PubMed ID: 34929447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High estrogen during ovarian stimulation induced loss of maternal imprinted methylation that is essential for placental development via overexpression of TET2 in mouse oocytes.
    Lu X; Mao J; Qian C; Lei H; Mu F; Sun H; Yan S; Fang Z; Lu J; Xu Q; Dong J; Su D; Wang J; Jin N; Chen S; Wang X
    Cell Commun Signal; 2024 Feb; 22(1):135. PubMed ID: 38374066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.
    Rasmussen KD; Jia G; Johansen JV; Pedersen MT; Rapin N; Bagger FO; Porse BT; Bernard OA; Christensen J; Helin K
    Genes Dev; 2015 May; 29(9):910-22. PubMed ID: 25886910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation.
    Hon GC; Song CX; Du T; Jin F; Selvaraj S; Lee AY; Yen CA; Ye Z; Mao SQ; Wang BA; Kuan S; Edsall LE; Zhao BS; Xu GL; He C; Ren B
    Mol Cell; 2014 Oct; 56(2):286-297. PubMed ID: 25263596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tet1 and Tet2 Protect DNA Methylation Canyons against Hypermethylation.
    Wiehle L; Raddatz G; Musch T; Dawlaty MM; Jaenisch R; Lyko F; Breiling A
    Mol Cell Biol; 2016 Feb; 36(3):452-61. PubMed ID: 26598602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA methylcytosine dioxygenase ten-eleven translocation 2 enhances lipopolysaccharide-induced cytokine expression in human dental pulp cells by regulating MyD88 hydroxymethylation.
    Wang X; Feng Z; Li Q; Yi B; Xu Q
    Cell Tissue Res; 2018 Aug; 373(2):477-485. PubMed ID: 29654353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells.
    Rasmussen KD; Berest I; Keβler S; Nishimura K; Simón-Carrasco L; Vassiliou GS; Pedersen MT; Christensen J; Zaugg JB; Helin K
    Genome Res; 2019 Apr; 29(4):564-575. PubMed ID: 30796038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion of Tet proteins results in quantitative disparities during ESC differentiation partially attributable to alterations in gene expression.
    Reimer M; Pulakanti K; Shi L; Abel A; Liang M; Malarkannan S; Rao S
    BMC Dev Biol; 2019 Jul; 19(1):16. PubMed ID: 31286885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.
    Kamdar S; Isserlin R; Van der Kwast T; Zlotta AR; Bader GD; Fleshner NE; Bapat B
    Clin Epigenetics; 2019 Mar; 11(1):54. PubMed ID: 30917865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Hydroxymethylcytosine is an essential intermediate of active DNA demethylation processes in primary human monocytes.
    Klug M; Schmidhofer S; Gebhard C; Andreesen R; Rehli M
    Genome Biol; 2013 May; 14(5):R46. PubMed ID: 23705593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS.
    Deplus R; Delatte B; Schwinn MK; Defrance M; Méndez J; Murphy N; Dawson MA; Volkmar M; Putmans P; Calonne E; Shih AH; Levine RL; Bernard O; Mercher T; Solary E; Urh M; Daniels DL; Fuks F
    EMBO J; 2013 Mar; 32(5):645-55. PubMed ID: 23353889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma.
    Gong F; Guo Y; Niu Y; Jin J; Zhang X; Shi X; Zhang L; Li R; Chen L; Ma RZ
    Oncotarget; 2017 Jan; 8(1):315-328. PubMed ID: 27852070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TET2: A Novel Epigenetic Regulator and Potential Intervention Target for Atherosclerosis.
    Liu Y; Peng W; Qu K; Lin X; Zeng Z; Chen J; Wei D; Wang Z
    DNA Cell Biol; 2018 Jun; 37(6):517-523. PubMed ID: 29653065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.
    Pan F; Wingo TS; Zhao Z; Gao R; Makishima H; Qu G; Lin L; Yu M; Ortega JR; Wang J; Nazha A; Chen L; Yao B; Liu C; Chen S; Weeks O; Ni H; Phillips BL; Huang S; Wang J; He C; Li GM; Radivoyevitch T; Aifantis I; Maciejewski JP; Yang FC; Jin P; Xu M
    Nat Commun; 2017 Apr; 8():15102. PubMed ID: 28440315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TET family proteins and 5-hydroxymethylcytosine in esophageal squamous cell carcinoma.
    Murata A; Baba Y; Ishimoto T; Miyake K; Kosumi K; Harada K; Kurashige J; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Yamamoto M; Oda S; Watanabe M; Nakao M; Baba H
    Oncotarget; 2015 Sep; 6(27):23372-82. PubMed ID: 26093090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic switching of active promoter and enhancer domains regulates Tet1 and Tet2 expression during cell state transitions between pluripotency and differentiation.
    Sohni A; Bartoccetti M; Khoueiry R; Spans L; Vande Velde J; De Troyer L; Pulakanti K; Claessens F; Rao S; Koh KP
    Mol Cell Biol; 2015 Mar; 35(6):1026-42. PubMed ID: 25582196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.